Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | HPGD | P15428 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593250 | 0.89 | HPGD (0.60) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL14395933 | 0.87 | KMT2A (0.67) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL276856 | 0.86 | KMT2A (0.68) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL279976 | 0.85 | KMT2A (0.67) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL2204276 | 0.81 | HDAC4 (0.66) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL8590837 | 0.76 | KMT2A (0.64) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL15259117 | 0.75 | KMT2A (0.62) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL280291 | 0.75 | KMT2A (0.52) | KMT2AHPGDSMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL6882924 | 0.73 | HPGD (0.65) | KMT2AHPGDSMN1; SMN2L3MBTL1RAB9A | |
| SCHEMBL31745206 | 0.73 | ALDH1A1 (0.64) | KMT2AHPGDSMN1; SMN2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| CN-101076519-A | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL IND LTD (JP) | 2007-11-21 | — | — | CN | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | KMT2A 3398/4885HPGD 1895/4885SMN1; SMN2 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.